As an epigenetic target, histone acetylation has great therapeutic value. Several disorders, including cancer, are associated with an increase in the activity of histone deacetylase enzymes (HDACs). The hydroxamate-group is employed in most HDAC-inhibitors, since it is a strong zinc-binding molecule (ZBG). Due to their toxicity and poor pharmacokinetic, hydroxamates are not a preferred cancer therapy option. As a result, a possible technique for increasing potency and selectivity is the development of non-hydroximate HDAC inhibitors